ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 7, 2021

8:30AM-10:30AM: Abstract Number: 0732

Topical Rofecoxib for OA of the Knee

Osteoarthritis – Clinical Poster II (0723–0738)

8:30AM-10:30AM: Abstract Number: 0727

Total Joint Replacements in Three Phase 3 Studies of Tanezumab in Patients with Osteoarthritis

Osteoarthritis – Clinical Poster II (0723–0738)

8:30AM-10:30AM: Abstract Number: 0517

TPMT and NUDT15 Genotype and Azathioprine Myelotoxicity in Patients with Inflammatory Conditions: Results from Real-World Clinical Practice

Genetics, Genomics & Proteomics Poster (0517–0533)

8:30AM-10:30AM: Abstract Number: 0893

Trajectories of Depressive Symptoms in Systemic Lupus Erythematosus over 7 Years

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

8:30AM-10:30AM: Abstract Number: 0526

Transcriptional Factor Profiling Denotes Specific Synovial Macrophage Heterogeneity

Genetics, Genomics & Proteomics Poster (0517–0533)

8:30AM-10:30AM: Abstract Number: 0523

Transcriptional Subsetting of SLE Patient Cohorts Based on Metabolic Pathway Activity

Genetics, Genomics & Proteomics Poster (0517–0533)

8:30AM-10:30AM: Abstract Number: 0783

Transmission Disequilibrium Testing Meets Next Generation Sequencing: Applying TDT to Whole Genome Data in Childhood-Onset Systemic Lupus Erythematosus

Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)

8:30AM-10:30AM: Abstract Number: 0550

Treatment Regimens and Outcomes in Systemic Sclerosis-associated Pulmonary Arterial Hypertension

Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)

8:30AM-10:30AM: Abstract Number: 0795

Treatment Response and Several Patient-reported Outcomes Are Early Determinants of Future Self-efficacy in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

8:30AM-10:30AM: Abstract Number: 0511

Tumor Necrosis Factor-α Modulates Endothelial-to-mesenchymal Transition and Increases Protein Tyrosine Phosphatase 1B

Cytokines & Cell Trafficking Poster (0508–0516)

8:30AM-10:30AM: Abstract Number: 0747

Understanding Heterogeneity in Patients’ Conceptualization of Treatment for Rheumatoid Arthritis: A Cluster Analysis

Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

8:30AM-10:30AM: Abstract Number: 0659

Understanding the Rheumatologic Population We Serve Through Objective Analysis of Referrals and Diagnoses: Does Perception Match Actual Data?

Measures & Measurement of Healthcare Quality Poster (0623–0659)

8:30AM-10:30AM: Abstract Number: PP01

Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic

Patient Perspectives Poster (PP01–PP09)

8:30AM-10:30AM: Abstract Number: 0790

Unraveling Heterogeneity Within ACPA-negative Rheumatoid Arthritis; The Subgroup of Patients with a Strong Clinical and Serological Response to Initiation of DMARD-treatment Favor Disease Resolution

RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

8:30AM-10:30AM: Abstract Number: 0549

Upregulation of Prostanoid EP2 Receptors and Meditation of Treprostinil Anti-Proliferative Effects in Scleroderma Smooth Muscle Cells

Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].